Favorable effects of the lipid-lowering and platelet antiaggregant Plafibride on the aging process of mice of the C57bl/6J strain.
It is known that an excessive intake of lipids and raised lipid levels in the blood accelerate many of the age-dependent pathologies. Therefore, it is probable that the administration of hypolipidemic agents delays to a certain degree the rate of aging. This concept has been experimentally tested in mice of the C57BL/6J strain treated with N-(2-p-chlorophenoxy) methylpropionil)-N'-morfolinomethylurea (Plafibride). The chemical was given in diet pellets at a dose of approximately 180 mg/kg body weight/day. There were no manifestations of toxicity despite the fact that treatment lasted 8 months. On the contrary, it seems that the aging process was favorably influenced since vigor and neuromuscular coordination were somewhat preserved in the treated mice in comparison to the controls. Moreover, old mice treated with Plafibride showed values for body and liver weights that were more similar to those of younger mice. These effects were especially evident in animals fed an hypercaloric diet enriched with fat and sucrose. The present experimental results suggest performing clinical studies for investigation of the effects of long-term treatment with Plafibride on the physiological and pathological manifestations of human aging.
D000375:Aging / Q000187:drug effects*; D000821:Animal Feed; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008062:Lipofuscin / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009929:Organ Size / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*
D000960:Hypolipidemic Agents; D008062:Lipofuscin; D002995:Clofibric Acid; C016894:plafibride; D002994:Clofibrate